Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

223 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-23

Study Completion Date

2025-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of HPV Vaccination to Catch up in the Emergence of Lesions of the Cervix

NCT03328013

HPV Vaccination Pap Smear Cervical Cancer +1 more

TERMINATED

Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)

NCT03653377

Mucoviscidosis

COMPLETED

HPV Vaccination in Women With Cystic Fibrosis

NCT03265743

Human Papillomavirus Infection

COMPLETED

Impact of Catch-up HPV Vaccination

NCT05462249

HPV HPV Vaccination Vaccine Preventable Disease +2 more

TERMINATED

Protective Efficacy of HPV Vaccination After Treatment of HPV Related Diseases

NCT05085093

HPV Vaccination、HPV Related Diseases、Protective Efficacy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Girls and young women with chronic condition are at higher risk for infections that can be prevented by vaccination. Human papillomavirus infection is very common, one of the three most common in the general population. A vaccine exists to significantly prevent this infection and its complications.

In France, it is advisable to vaccinate girls and boys from the age of 9 years and as soon as possible in the case of acquired immunodeficiency since these patients are more likely to be suffering from cancer induced by the human papillomavirus.

In France, the overall rate of vaccination coverage for girls is 21%, which is significantly lower than in several other industrialized countries.

The vaccination coverage rate for human papillomavirus in patients with chronic diseases may be even lower.

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic condition and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Papillomavirus Vaccine Chronic Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic condition

Girls and young women between the ages of 11 and 20 suffering from chronic condition

Questionnaire

Intervention Type OTHER

Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.

The questionnaire is completed by the patient.

Control

Girls and young women between the ages of 11 and 20 in good health

Questionnaire

Intervention Type OTHER

Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.

The questionnaire is completed by the patient.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.

The questionnaire is completed by the patient.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Information and non-opposition of major patients and holders of parental authority of minor patients and minor patients
* Girls and young women aged 11 to 20
* To be followed at the Necker-Enfants Malades Hospital ("chronic condition" group)
* To be followed at the Specialized Medical Center for Children and Adolescents ("control" group)
* Have a chronic condition ("chronic condition" group) :

* Diabetes type 1
* Metabolic diseases
* Patients followed in immuno-hematology
* Cystic Fibrosis
* Sickle
* Kidney transplant
* Heart Disease
* Inflammatory bowel diseases
* Rare anorectal and pelvic anomalies
* Live in France
* Comprehension of the French language (oral and written)

Exclusion Criteria

* Have a contraindication to the HPV vaccine - Gardasil 9 (Vidal Hoptimal, 2018)
* Have a contraindication to the HPV vaccine - Gardasil (Vidal Hopitmal, 2018)
* Have a contraindication to HPV vaccine - Cervarix (Vidal Hoptimal, 2018)

Minimum Eligible Age

11 Years

Maximum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No